Cantor Fitzgerald Has Negative View of ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research report issued on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($2.91) per share for the year, down from their prior estimate of ($2.72). Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Several other equities research analysts also recently commented on ARTV. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday. Wedbush restated an “outperform” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $20.40.

Artiva Biotherapeutics Stock Down 8.8 %

Shares of ARTV stock opened at $3.64 on Thursday. The stock’s fifty day simple moving average is $4.84 and its 200 day simple moving average is $9.33. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $152,234,000. Franklin Resources Inc. acquired a new stake in Artiva Biotherapeutics in the third quarter worth about $7,435,000. Geode Capital Management LLC raised its holdings in Artiva Biotherapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Samsara BioCapital LLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $4,506,000. Finally, Wellington Management Group LLP bought a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.